Novel catalase loaded nanocores for the treatment of inflammatory bowel diseases
Source abstract
Abstract
Inflammatory bowel disease (IBD) is an inflammatory disorder of the digestive tract reported to be primarily caused by oxidative stress. In this study, alginate encapsulated nanoceramic carriers were designed to deliver acid labile antioxidant enzyme catalase orally. Complete system was characterized for size, loading efficiency, in vitro antioxidant assay and in vitro release. The prepared nanoceramic system was found to be spherical with diameter of 925 ± 6.81 nm. The in vitro release data followed the Higuchi model in acidic buffer whereas in alkaline pH sustained and almost first order release of enzyme was observed up to 6 h.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Advanced Drug Delivery Systems · Nanoparticle-Based Drug Delivery · Drug Solubulity and Delivery Systems
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
University Institute of Pharmacy, Pt. Ravishankar Shukla University, Raipur, India
Funding
UGC-BSR · DST-FIST · UGC-MRP
References (30)
Show source-provided references
1. 10.1016/j.actbio.2012.02.01210.1016/j.actbio.2012.02.012 ↗
2. 10.4103/1319-3767.17375310.4103/1319-3767.173753 ↗
3. 10.1128/AEM.03296-1310.1128/AEM.03296-13 ↗
4. 10.1016/j.intimp.2015.12.01210.1016/j.intimp.2015.12.012 ↗
5. Farihurst D. · 2013
6. 10.1177/088532820910401810.1177/0885328209104018 ↗
7. 10.1016/0891-5849(90)90092-W10.1016/0891-5849(90)90092-W ↗
8. Ibrahim RY · Int J Clin Exp Med · 2015 · 8 · 21861
9. 10.1007/BF0012038610.1007/BF00120386 ↗
10. 10.4103/0973-1296.17791310.4103/0973-1296.177913 ↗
11. 10.3109/1073119940911787610.3109/10731199409117876 ↗
12. 10.1002/path.140910.1002/path.1409 ↗
13. Kumagi S · Rinsho Byori · 2003 · 2 · 126
14. 10.1016/j.progpolymsci.2011.06.00310.1016/j.progpolymsci.2011.06.003 ↗
15. 10.1016/S0731-7085(97)00029-010.1016/S0731-7085(97)00029-0 ↗
16. Mc Cole DF · FASEB J · 2008 · 22 · 1189
17. 10.1016/j.redox.2015.10.00610.1016/j.redox.2015.10.006 ↗
18. 10.1016/j.intimp.2011.02.00410.1016/j.intimp.2011.02.004 ↗
19. 10.1080/1071754049043397610.1080/10717540490433976 ↗
20. Peppas NA. · Pharm Acta Helv · 1985 · 60 · 110
21. Poinern G · Am J Biomed Eng · 2013 · 6 · 48
22. 10.1016/j.ultsonch.2009.01.00710.1016/j.ultsonch.2009.01.007 ↗
23. Rana SV · Indian J Med Res · 2014 · 139 · 568
24. 10.1248/bpb.29.179010.1248/bpb.29.1790 ↗
25. 10.1080/0363904070153947910.1080/03639040701539479 ↗
26. 10.1007/s10620-006-9622-210.1007/s10620-006-9622-2 ↗
27. 10.1016/S0169-409X(01)00112-010.1016/S0169-409X(01)00112-0 ↗
28. 10.1517/17425247.2012.74584810.1517/17425247.2012.745848 ↗
29. 10.1615/CritRevTherDrugCarrierSyst.201501109510.1615/CritRevTherDrugCarrierSyst.2015011095 ↗
30. 10.3748/wjg.v20.i1.9110.3748/wjg.v20.i1.91 ↗